Dynamics of rectal balloon implant shrinkage in prostate VMAT
Influence on anorectal dose and late rectal complication risk

Ben G. L. Vanneste1 · Y. van Wijk1 · L. C. Lutgens1 · E. J. Van Limbergen1 · E. N. van Lin2 · K. van de Beek3 · P. Lambin1 · A. L. Hoffmann1,4,5

Received: 16 June 2017 / Accepted: 19 September 2017 / Published online: 16 October 2017
© The Author(s) 2017. This article is an open access publication.

Abstract
Purpose To assess the effect of a shrinking rectal balloon implant (RBI) on the anorectal dose and complication risk during the course of moderately hypofractionated prostate radiotherapy.
Methods In 15 patients with localized prostate cancer, an RBI was implanted. A weekly kilovolt cone-beam computed tomography (CBCT) scan was acquired to measure the dynamics of RBI volume and prostate–rectum separation. The absolute anorectal volume encompassed by the 2 Gy equieffective 75 Gy isodose (V75Gy) was recalculated as well as the mean anorectal dose. The increase in estimated risk of grade 2–3 late rectal bleeding (LRB) between the start and end of treatment was predicted using nomograms. The observed acute and late toxicities were evaluated.

Results A significant shrinkage of RBI volumes was observed, with an average volume of 70.4% of baseline at the end of the treatment. Although the prostate–rectum separation significantly decreased over time, it remained at least 1 cm. No significant increase in V75Gy of the anorectum was observed, except in one patient whose RBI had completely deflated in the third week of treatment. No correlation between mean anorectal dose and balloon deflation was found. The increase in predicted LRB risk was not significant, except in the one patient whose RBI completely deflated. The observed toxicities confirmed these findings.

Conclusions Despite significant decrease in RBI volume the high-dose rectal volume and the predicted LRB risk were unaffected due to a persistent spacing between the prostate and the anterior rectal wall.

Keywords Volumetric modulated arc therapy · Radiotherapy · Rectum · Volume stability · Toxicity
schen Beginn und Ende der Behandlung wurde mit Nomogrammen vorhergesagt. Die beobachteten akuten und späten Toxizitäten wurden ausgewertet.

**Ergebnisse** Es wurde eine signifikante Schrumpfung der RBI-Volumina beobachtet, mit einem durchschnittlichen Volumen am Ende der Behandlung von 70,4 % des Baseline-Volumens. Obwohl die Prostata-Rektum-Trennung im Verlauf der Therapie deutlich abnahm, betrug diese durchgehend mindestens 1 cm. Es wurde kein signifikanter V\(^{75Gy}\)-Anstieg des Anorektums beobachtet, außer bei einem Patienten, dessen RBI in der dritten Behandlungswoche vollständig entleert war. Zwischen der mittleren anorektalen Dosis und der Ballonvolumenabnahme wurde keine Korrelation festgestellt. Die Zunahme des LRB-Risikos war nicht signifikant, außer bei dem Patienten mit vollständig entleertem RBI. Die beobachteten Toxizitäten bestätigten diese Befunde.

**Schlussfolgerung** Trotz signifikanter Abnahme des RBI-Volumens waren das Hochdosis-Rektumvolumen und das vorhergesagte LRB-Risiko aufgrund eines anhaltenden Abstands zwischen der Prostata und der anterioren Rektumwand davon nicht nachteilig betroffen.

**Schlüsselwörter** Volumenmodulierte Arc-Therapie · Strahlentherapie · Rektum · Volumenstabilität · Toxizität

External beam radiation therapy (EBRT) is an effective curative treatment option for patients with localized adenocarcinoma of the prostate compared to surgery [1]. Increasing radiation dose is associated by increased control; however, this is correlated with an increased potential risk of gastrointestinal (GI) toxicity, with possibly a decrease in the quality of life [2–4]. Despite the development of advanced treatment techniques like intensity-modulated radiation therapy, volumetric arc therapy, and image-guided radiotherapy, sparing of the rectal wall is a prerequisite for safe delivery of high doses to the prostate. This makes the rectum the dominant dose-limiting organ at risk in prostate EBRT. To spare the rectum, artificial spacing material has been used for insertion into the retroprostatic space. Implantable rectum spacers (IRS) separate the anterior rectal wall from the prostate by creating an artificial distance between these organs. As such they reduce the dose exposure to the rectum, consequently decreasing the risk of GI toxicity. Different types of IRS exist, all of which are implanted through a transperineal approach. Hyaluronic acid [5] and collagen implants [6] are physiological compounds made of substances that are naturally present in the human body. Potential side effects for transmission of infectious agents or immunological reactions have been reported [7]. Therefore, commercially available spacers based on polyethylene glycol (PEG) hydrogels [8] and biodegradable saline-filled rectal balloon implants (RBI) [9] have been developed. Recently Wolf et al. [10] compared PEG and RBI spacer technologies in 59 prostate cancer patients undergoing radiation treatment and concluded that the RBI was superior in reducing rectum dose, whereas the PEG hydrogel spacer had a better volume consistency with respect to the duration of treatment. They reported an early and sudden RBI volume decline in 4 out of 16 patients, and an average volume loss of >50% in the remaining 12 patients during the full course of treatment over 8 weeks of a normofractionated radiotherapy regimen comprising 41 fractions.

The aim of our study was to evaluate the RBI volume stability and the dosimetric effect of RBI volume shrinkage on the anorectum and to estimate the 3-year risk of grade 2–3 late rectal bleeding (LRB) during the course of a moderately hypofractionated EBRT regimen comprising 28 fractions. We tested the hypotheses that despite of an expected RBI volume decrease over time there is no significant increase in the absolute anorectal volume encompassed by the 2 Gy equieffective dose of 75 Gy (V\(^{75Gy}\)) and in the mean anorectal dose, both of which are considered relevant parameters for predicting LRB. We also tested the hypothesis that there is no correlation between RBI deflation and mean anorectal dose. In addition, we hypothesized that the predicted increase in risk of LRB resulting from the volume decrease of the RBI is insignificant. Furthermore, we postulated that this predicted status quo of LRB risk can be explained by a persistent prostate–rectum separation of at least 1 cm during the whole course of treatment. Finally, we reported the observed acute and—as far as possible—late toxicities.

**Materials and methods**

**Patient selection**

After approval by the institutional review board (number 14-38-03/09-internal-6335), 15 consecutive prostate cancer patients were prospectively included in this study between June 2015 and March 2016. Patients with a histologically confirmed, localized adenocarcinoma of the prostate were enrolled in this study to receive an RBI (Bio-

**Table 1** Patient (N = 15) and tumor characteristics

| Age (years; median [range]) | 72 [63–77] |
|----------------------------|------------|
| Prognostic risk group$^a$ (no. of patients) | 1 – Low risk 1 (7%) |
| 2 – Intermediate risk | 5 (33%) |
| 3 – High risk | 9 (60%) |

$^a$Low risk: no risk factors: PSA <10 ng/ml; Gleason score <7; cT stage <2b; Intermediate risk: PSA 10–20 ng/ml and/or Gleason score = 7 or cT stage = 2b/c; High risk: PSA >20 ng/ml or Gleason score >7 or cT stage >2b/c

© Springer
Fig. 1  Color-wash isodose distribution projected on an axial CT slice before (a) and after RBI implantation (b) in the same patient with the planning target volume in red. Without RBI (a), the high-dose region >80% (green isodose) overlaps with the entire ventral part of the rectum (black line), whereas with the RBI in situ (b) the rectum is exposed to a dose <65% (blue isodose).

Protect Ltd, Israel). All patients had signed an informed consent form. The patient and tumor characteristics are summarized in Table 1. Patients who had been classified as intermediate risk were prescribed additional neoadjuvant hormonal therapy for 6 months [11]. The high-risk patients were offered an additional 1.5 years hormonal therapy as an extension of the 6-month neoadjuvant therapy after EBRT. All patients underwent magnetic resonance imaging (MRI) to exclude extraprostatic spread. Dorsal extraprostatic disease extension (stage T3a/4) was an exclusion criteria, as well as distant metastatic disease, inflammatory bowel disease and previous pelvic EBRT.

**RBI implantation procedure**

An RBI was implanted in these patients between the prostate and the anterior rectal wall 7–10 days prior to the start of EBRT. The injection technique has been previously described in detail [12]. A short general anesthesia is preferred at our department. However, the implantation procedure can be also performed under local or spinal anesthesia. First, four fiducial markers (PolyMark™, CIVCO, Orange City, IA, USA) were implanted intraprostatically for daily position verification. The RBI was implanted transperineally under biplane transrectal ultrasonography guidance. A bubble-free (sterile) saline solution was used to fill and inflate the RBI. The saline solution was mixed with approximately 1.5 cm³ iodinated contrast medium to enhance the visualization of the RBI on computed tomography (CT) scans. The injected volume was varied, depending on the volume of the prostate. Because the RBI should not be filled to achieve a prostate–rectum separation larger than 30 mm, we adapted the volume of the RBI to the volume of the prostate: small prostates (<35 ml) do not need the maximum RBI volume to guarantee a prostate–rectum separation of at least 1 cm, which is considered as a conclusive spread [13].

**Target volume definition, dose prescription, and treatment planning**

Each patient underwent a CT scan and MRI scan 5–7 days after RBI implantation in supine position with a slice thickness of 3 mm for treatment planning and target volume delineation purposes, respectively. One hour prior to image acquisition, patients were instructed to first empty their bladder, then drink 300 ml of water to have a full bladder, and empty their bowel. No use of laxative was recommended. The CT and MRI scans (balanced turbo field echo sequence with isotropic 0.5 mm in-plane resolution) were coregistered based on the fiducial markers.

Delineation of the prostate (CTV = clinical target volume) was performed on the T2-weighted MRI scan, while the RBI and the organs at risk were delineated on the CT scan (Fig. 1). In case the CT and MR images showed different prostate shapes and volumes (e.g., due to differences in rectal filling), the MR imaging was repeated. The first planning target volume (PTV1) was constructed according to the institutional protocol by expanding the CTV with 10, 7 and 6 mm in cranial–caudal, anterior–posterior, and left–right direction, respectively. A second PTV (PTV2) was defined as a 5 mm isotropic expansion of the CTV, with exclusion of the anorectum and bladder. All treatment plans were designed for dose delivery with a volumetric modulated arc technique (VMAT) using 10 MV photon beams (Eclipse Version ICD-10, Varian Medical Systems Inc., Palo Alto, CA, USA). The prescribed dose to PTV1 and PTV2 was 65.8 and 70 Gy, in 28 fractions of 2.35 and 2.5 Gy, respectively [14]. With $\alpha/\beta = 3$ Gy for late rectal toxicity, the maximum 2 Gy equieffective dose (EQD2) in the anorectum for this type of plan is 77 Gy [15]. No density override for the iodine-containing RBI was performed because it was assumed that the contrast medium that was present in the RBI at the time of CT scanning and treatment planning remained present during treatment delivery. The overall treatment time was 7 weeks, at 4 fractions a week. The dose–volume constraints fulfilled the institutional pro-
Table 2  RBI volume and minimum prostate–rectum distance dynamics

|                  | RBI volume (cm³; median [range]) | Prostate–rectum distance (cm; median [range]) |
|------------------|----------------------------------|-----------------------------------------------|
| Planning CT      | 20.0 [12.9–22.6]                 | 2.3 [1.9–2.9]                                 |
| CBCT 1           | 19.6 [12.8–21.7]                 | 2.2 [1.8–2.8]                                 |
| CBCT 7           | 16.0 [12.8–20.7]                 | 2.0 [1.7–2.5]                                 |
| CBCT 11          | 15.8 [11.7–20.7]                 | 1.9 [1.6–2.4]                                 |
| CBCT 15          | 15.6 [11.7–20.6]                 | 1.9 [1.5–2.4]                                 |
| CBCT 19          | 14.5 [11.3–20.0]                 | 1.9 [1.3–2.4]                                 |
| CBCT 23          | 14.0 [9.6–19.8]                  | 1.7 [1.1–2.3]                                 |
| CBCT 27          | 11.9 [6.3–19.8]                  | 1.4 [1.1–2.3]                                 |

RBI rectal balloon implant, CBCT cone-beam computed tomography

tocol, which is based on the QUANTEC guidelines [16]. All patients underwent daily X-ray based position verification and repositioning based on the intraprostatic fiducial markers.

**RBI volume and distance dynamics**

To assess the volume stability of the RBI over time, a weekly kilovolt cone beam computed tomography (CBCT) scan was acquired in treatment position prior to irradiation, respectively at fractions 1, 7, 11, 15, 19, 23, and 27. The resulting 105 CBCT scans were imported into the treatment planning system for delineation and subsequent 3D volumetry of the RBI. Furthermore, the minimum distance between the prostate and the anterior rectal wall was measured at midprostate level in anterior–posterior direction. Two observers independently delineated the RBI (RG and BV) and the anorectum (DH and BV). The anorectal structure consists of the rectum and the anal canal. The rectum was delineated from the top of the anal canal up to the rectosigmoid flexure. The anal canal was considered as the distal 3 cm of the anorectum. Six to nine months after RBI implantation, an MRI scan was acquired to evaluate the biodegradability of the RBI.

**Anorectal dose estimation**

To assess the dosimetric consequences of RBI shrinkage on the anorectum, the planned dose distribution of the three patients with the largest observed RBI volume reduction was recalculated on the weekly acquired CBCT images, while keeping all planning parameters (e.g., beam arrangement, field size, fluence maps, monitor units) the same as for the initial, CT-based treatment plan. The dose–volume histogram (DVH) for the anorectum obtained from the treatment plan was converted into EQD2, using the Withers formula [17]:

\[
EQD2_{\alpha/\beta} = D \cdot \frac{d + \frac{\alpha}{\beta}}{2 + \frac{\alpha}{\beta}},
\]

where \(\alpha/\beta = 3\) Gy for late rectal toxicity, \(D\) is the total dose, and \(d\) is the dose per fraction. All dose–(volume) parameters were obtained from the EQD2,–converted DVH. The absolute \(V_{75Gy}\) of the anorectum was compared between the CT and CBCT plans: in the 3 cases with the largest RBI volume decrease the weekly CBCT images were compared. For the remaining patients, only the CBCT images of the last week (CBCT 27) were used for comparison of the anorectal \(V_{75Gy}\) against the CT-based plan. The EQD2,–converted mean anorectal dose was calculated for the planning CT and the final CBCT for all patients.

**Complication risk estimation**

To assess the effect of the RBI volume decrease on the 3-year risk of grade 2–3 LRB, a set of previously published multifactorial nomograms were used [18]. These nomograms use clinical parameters (use of anticoagulants, hormonal therapy, or antihypertensives; pelvic node irradiation; presence of diabetes or hemorrhoids; and a history of pre-RT abdominal surgery), in addition to dosimetric parameters (mean rectal dose and the percentage of the anorectum volume receiving at least an EQD2 of 75 Gy) to predict the risk of late rectal bleeding. The nomograms were applied to the initial treatment plans and the plans performed on the final CBCT images for each patient. The results were used to estimate the largest change in predicted complication risk due to shrinkage of the RBI.

**Observed toxicity assessment**

The complications were recorded in terms of Common Terminology Criteria for Adverse Events (Version 4.03) [19]. Acute gastrointestinal (GI) and genitourinary (GU) toxicities were scored in the 2nd, 4th, 6th week of treatment and 3 months after its completion. Late toxicities were scored
in the 6th, 9th, and—in case if possible—12th, and 18th months after treatment completion.

**Statistical analysis**

The statistical analyses were carried out using the Statistics Toolbox of MATLAB (Version 10.2, The MathWorks, Natick, MA, USA) software. The paired-samples Wilcoxon signed rank test was applied to test for a significant decrease in volume of the RBI on weekly acquired CBCT scans, and for a significant decrease in distance between prostate and rectum. This test was also applied to test for a significant increase in predicted complication risk between the first and last fraction. All statistical tests were one-sided, with $P < 0.05$ considered to be statistically significant.

**Results**

**RBI volume and distance stability**

The median injected and delineated RBI volumes were 17.0 cm$^3$ (range 9–17 cm$^3$) and 20.0 cm$^3$ (range 12.9–22.6 cm$^3$), respectively. Volume differences are explained by the fact that the delineated RBI structure comprises both the injected saline solution and the RBI envelope. Two
patients were excluded from the stability analysis because in one patient CBCT scans were missing due to a protocol violation and in another patient the RBI had disappeared on CBCT in the third week of treatment as no contrast medium could be detected. For the remaining 13 patients, the descriptive statistics of the RBI volume dynamics are summarized in Table 2 and depicted in Fig. 2. The median RBI volumes at fractions 1, 15, and 27 were 19.6 (range 12.8–21.7), 15.6 (range 11.7–20.6), and 11.9 cm³ (range 6.3–19.8 cm³), respectively. The weekly decrease in absolute RBI volume was significant for all time points, with an average volume loss of 29.6% at fraction 27 relative to baseline. The largest relative volume decrease occurred during the first week (i.e., between fraction 1 and 7), and after fraction 19 (Fig. 2). The median volume loss relative to baseline was 25% (range 5.7–54.9%). The descriptive statistics of the prostate–rectum distance dynamics are also summarized in Table 2. Although the weekly decrease of minimum prostate–rectum distance was significant for all time points, this distance remained greater than 1 cm at all times.

RBI resorption

Six to nine months after completion of EBRT a residual rest of the RBI envelope was visible on T2-weighted MRI in only 1 out of 15 (7%) patients; no contrast medium or saline solution could be observed. Neither space-occupying effects nor complications (infections, perforations, fibrosis) were observed in any of the patients.

Anorectal dosimetry

In the patient whose RBI had disappeared on the CBCT scan in the third week of treatment, the \( V_{75Gy} \) of the anorectum significantly increased from 0 to 4.3 and 5.9 cm³ at fraction 1, 11, and 27, respectively (patient 9, Fig. 3). In the other two patients (numbers 5 and 12) exhibiting the largest RBI volume decrease (45 and 52% of the original volume, respectively) a significant increase in absolute \( V_{75Gy} \) of the anorectum was only observed in the CBCT scan of fraction 23 (patients 5 and 12, Fig. 3). Furthermore, the RBI deflation did not lead to significant increase in \( V_{75Gy} \) \((p = 0.577)\). Among the remaining patients there was only one patient who showed an increase of \( V_{75Gy} \) from 0 cm³ on the CT plan to 3.6 cm³ on the CBCT plan (Table 3). In 2 out of 11 patients, the \( V_{75Gy} \) remained 0 for both the CT and CBCT scans. In 6 patients, even a slight decrease of \( V_{75Gy} \) was determined. The increase in \( V_{75Gy} \) for all patients except the one of whom the RBI disappeared was not significant \((P = 0.57)\). The increase in mean anorectal dose was significant \((P = 0.02)\); however, no correlation was found between the mean anorectal dose and the volume of the RBI \((P = 0.3)\). The correlation between the anorectal volume and the anorectal mean dose was significant \((P = 0.005)\).

Risk of late rectal bleeding

In the patient whose RBI had completely deflated in the third week of treatment (patient 9), the risk of LRB was predicted to increase from 4.0 to 9.8%. For the two patients with the largest observed RBI shrinkage (patients 5 and 12) the predicted increase in LRB risk was 0 and 0.2%, respectively (Fig. 4). The largest increase in complication risk predicted for the remaining patients was 3.4%, resulting from a RBI volume decrease of 32%. The difference between the predicted risk of LRB at the start of treatment and the end of treatment, excluding the patient with the deflated RBI, was not significant \((P = 0.07)\) (Fig. 5).

Observed toxicities

No acute grade 3 or 4 toxicities were reported during treatment or 3 months after completion. Overall, 5 patients (33%) experienced no toxicity, 6 patients (40%) had grade 1 GU toxicities, and 4 patients (27%) had grade 2 GU toxicities. During the course of therapy, in 4 patients (27%) grade 1 GI toxicity was observed, but no grade 2 or more acute GI toxicities.

No late grade 3 GI toxicity has been reported. Late grade 2 GI toxicity was observed in 1 patient: the rectal bleeding started at 9 months after radiation. This was the patient whose RBI had completely deflated in the third week of treatment. Grade 1 GI and GU late toxicities were reported in 2 patients.
Discussion

This study provides the first evaluation of RBI volume stability that is based on weekly CBCT measurements during the full course of EBRT. As previously reported in literature, an RBI volume decrease was expected over time. We analyzed the dosimetric consequences of this phenomenon and predicted the increase in risk of 3-years grade 2–3 late rectal bleeding resulting from a shrinking RBI to assess its potential clinical impact. Moreover, the observed acute and early late toxicities were adjusted.

GI toxicity is the major treatment-related side effect in prostate cancer radiotherapy: the rates of acute and chronic grade ≥2 rectal toxicity has increased by dose-escalated EBRT (up to a dose of 78 Gy) compared with lower doses (e.g., 68 Gy) from 3 to 20% and from 5 to 21%, respectively [20–24]. Therefore, it is advantageous to push the rectal wall out of high-dose regions by implantation of an IRS device [25, 26]. So far, most studies in the literature have reported on the use of a PEG hydrogel as an IRS [27–31]. The RBI has some practical advantages [9]. First of all, postimplant correction of the RBI position is possible; if the RBI is dispositioned, it can be easily deflated and replaced, whereas liquid spacers (PEG hydrogels, hyaluronic acid, human collagen) do not permit any correction once being injected [9, 12]. In addition, a chemical reaction is required to occur in PEG hydrogels, which limits the implantation time. Furthermore, since the RBI inflates to a predetermined and predictable shape, the learning curve to obtain an adequate implant is less steep than for PEG hydrogels. In addition, due to the defined shape and homogenous hypodense signal, the RBI has an excellent CT visibility, which is most advantageous for treatment planning and CBCT-based evaluations. Besides, some amount of iodine contrast can be added to the saline to enhance the visualization of the RBI on CT and CBCT scans (Fig. 1). Moreover, because the RBI is a closed system, there is no risk of air or hydrogel injection into vessels.

Nevertheless, disadvantages of the RBI have also been reported. Recently Wolf et al. [10] described an early deflation effect. They reported an average volume loss of >50% during a full treatment course of 37–41 fractions (8 weeks). The volumes they estimated were mainly based on measurements of the diameters of the RBI on two orthogonal X-ray images and calculations by the volume formula for an ellipsoid cylinder. The measurements were only performed on CBCT scans of fractions 20 and 38. Data on the dynamics of the prostate–rectum separation over time are missing in their study. Wolf et al. only recalculated one treatment plan on a CBCT scan for a single patient whose RBI showed a significant volume loss of 58%, and reported an increase of 9.2 cm³ for the rectum volume encompassed by the 95% isodose. We measured 3D volume changes on weekly CBCT scans and observed that a prostate–rectum separation of at least 1 cm is maintained during the full treatment course, except in the patient where the RBI deflated. The persistent spread of at least 1 cm means that also for other RT techniques like 3D conventional EBRT, intensity-modulated radiotherapy, or proton therapy, the sustained spread is considered as enough for protecting the anorectal structures [13].

By evaluating the dose on the anorectal structure, we observed that the $V_{75\text{Gy}}$ of the anorectum steadily increased only in one patient whose RBI disappeared completely in the third week of treatment. In the 2 remaining patients where the RBI shrank most, the $V_{75\text{Gy}}$ changed significantly in only two CBCT scans during the whole treatment course, but not in the last CBCT scan. This effect was caused by a difference in rectal filling (inclusion of gas bubbles and/or stool). The distance between the prostate and anorectum was still enlarged due to the presence of the RBI. However, the distance between the prostate and anorectum at the level of the cranial part of the rectum (above the RBI) could decrease incrementally. This is especially the case when the rectal filling is increased dramatically, and when seminal vesicles are irradiated. In this situation, the cranial part of the rectum above the RBI anorectum could receive a higher dose. Furthermore, the RBI could exert pressure on the rectum and thereby decrease the rectal volume being exposed to an intermediate and a high dose and increase the volume being exposed to low doses, with unknown clinical consequences. To reduce the low- and intermediate-dose levels, a different treatment planning technique using either an arc technique with an avoidance region near the rectum or using strictly anterior and lateral beams would be required.
By applying multifactorial nomograms on the initial treatment plan and on the final treatment plan, the predicted increase in risk of late rectal bleeding was analyzed. This showed that for the patient with the deflated RBI, the risk considerably increased, emphasizing the effect of the device. For the patient whose RBI had completely deflated, a significant increase in the risk of late rectal bleeding was predicted by the nomogram (Fig. 5). This was confirmed by the late rectal bleeding event 9 months after treatment. For the remaining patients, there was no significant increase in predicted complication risk, suggesting that the decrease in RBI volume has little impact on the effectiveness of the RBI. Some fluctuations in predicted toxicity risk can be seen, but these are likely also due to the rectal filling. Indeed, besides the distance between the rectal wall and the prostate, the rectum size could be a possible predictor of GI toxicity [32–35].

A previous study reported a sudden complete deflation of the RBI in 4 out of 16 patients three weeks after implantation [10]. In our series, one patient experienced such a sudden complete deflation three weeks after implantation. A possible explanation was a nonoptimal positioning: the RBI was positioned more caudally than the others, with the tip of the RBI in the pelvic muscle. Because of this positioning, an excessive force was required to inflate the RBI, which could have damaged the sealing mechanism. Another possible explanation of early deflation could be an excessive filling of the RBI (i.e., prostate–rectum separation larger than 30 mm) with bursting and consequent loss of function: each RBI is handmade, and one has to be sure not to exceed the maximum volume allowed that is indicated on the label of the product.

A limitation of this study is the small number of patients included. As this was a feasibility study, only 15 patients were included. Furthermore, there was no prior consensus on the level and window settings of the CBCT scans, which might have influenced the volumetric results. In addition, the CBCT scans were acquired at different time points and, hence, revealed different bladder and rectum filling, thus, adding extra uncertainty to the comparison performed. Furthermore, the nomograms used are not validated for patients treated with a RBI. More research is needed in larger patient cohorts to obtain more evidence. Finally, we evaluated weekly time points, and not daily, which later could be more representative for the whole treatment.

The RBI was successfully implanted in all 15 patients. The mean RBI volumes revealed an average volume of 70.4% of baseline at the end of treatment. Despite the weekly RBI shrinkage to be significant, neither significant increase in absolute $V_{75Gy}$ of the anorectum nor in predicted LRB risk were observed over the full treatment course of our moderately hypofractionated EBRT regimen. Although the minimum prostate–rectum distance showed a significant decrease, it was at least 1 cm during the full treatment course, indicating that such spacing is sufficient to reduce the anorectal $V_{75Gy}$ of a treatment plan delivered by a volumetric modulated arc technique. In patients experiencing a complete deflation of the RBI, the absolute $V_{75Gy}$ of the anorectum is expected to increase significantly, and so is the predicted risk of late rectal bleeding, and the observed toxicity. We advise to acquire imaging by CBCT scans at regular times during the course of treatment to assess deflation dynamics of the RBI. Only when the prostate–rectum distance decreases to less than 1 cm is a treatment plan adaptation recommended.

Acknowledgements The authors thank Renee Granzier, Debbie Herfs, Janneke Bovendeerd, and Marlies Lendfers for their help with the delineations and treatment planning on the cone-beam CT scans.

Compliance with ethical guidelines

Conflict of interest B.G.L. Vanneste, Y. van Wijk, L.C. Lutgens, E.J. Van Limbergen, E.N. van Lin, K. van de Beek, P. Lambin and A.L. Hoffmann declare that they have no competing interests.

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
References

1. Hamdy FC, Donovan JL, Lane JA, Mason M, Metcalfe C, Holling P et al (2016) 10-year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer. N Engl J Med 375(15):1415–1424
2. Fonteyne V, Ost P, Vanpachtenbeke F et al (2014) Rectal toxicity after intensity modulated radiotherapy for prostate cancer: which rectal dose volume constraints should we use? Radiother Oncol 13(3):398–403
3. Vanneste BG, Van De Voorde L, de Ridder RJ, Van Limbergen EJ, Lambin P, van Lin EN (2015) Chronic radiation proctitis: tricks to prevent and treat. Int J Colorectal Dis 30(10):1293–1303
4. Musanuru HB, Quon H, Davidson M et al (2016) Dose-escalation of five-fraction SABR in prostate cancer: toxicity comparison of two prospective trials. Radiother Oncol 118(1):112–117
5. Prada PJ, Fernández J, Martínez AA et al (2007) Transperineal injection of hyaluronic acid in anterior perirectal fat to decrease rectal toxicity from radiation delivered with intensity modulated brachytherapy or EBRT for prostate cancer patients. Int J Radiat Oncol Biol Phys 69(1):95–102
6. Noyes WR, Hosford CC, Schultz SE (2012) Human collagen injections to reduce rectal dose during radiotherapy. Int J Radiat Oncol Biol Phys 82(5):1918–1922
7. Prendes BL, Yung KC, Likhterov I et al (2012) Long-term effects of injection laryngoplasty with a temporary agent on voice quality and vocal fold position. Laryngoscope 122(10):2227–2233
8. Pinkawa M, Corral NE, Caffaro M (2011) Application of a spacer gel to optimize three-dimensional conformal and intensity modulated radiotherapy for prostate cancer. Radiother Oncol 100(3):436–441
9. Melchert C, Gez E, Bohlen G et al (2013) Interstitial biodegradable balloon for reduced rectal dose during prostate radiotherapy: results of a virtual planning investigation based on the pre- and post-implant imaging data of an international multicenter study. Radiother Oncol 106(2):210–214
10. Wolf F, Gaisberger C, Ziegler I et al (2015) Comparison of different rectal spacers in prostate cancer external beam radiotherapy in terms of rectal sparing and volume consistency. Radiother Oncol 116(2):221–225
11. Denham JW, Steigler A, Tai KH, Joseph D, Matthews J, Atkinson C, Spry NA, Turner S, North J, Christie D, Wynne C, Lamb DS (2013) Paradoxical metastatic progression following 3 months of neo-adjuvant androgen suppression in the TROG 96.01 trial for men with locally advanced prostate cancer. Radiother Oncol 107(2):123–128
12. Vanneste BG, van de Beek K, Lutgens L, Lambin P (2017) Implantation of a biodegradable rectum balloon implant: tips, tricks and pitfalls. Int Braz J Urol 24:2017. https://doi.org/10.1590/S1677-5538.IBJU.2016.0494
13. Susil RC, McNutt TR, DeWeese TL, Song D (2010) Effects of prostate-rectum separation on rectal dose from external beam radiotherapy. Int J Radiat Oncol Biol Phys 76(4):1251–1258
14. Kupelian PA, Willoughby TR, Reddy CA, Klein EA, Mahadevan A (2007) Hypofractionated intensity-modulated radiotherapy (70 Gy at 2.5 Gy per fraction) for localized prostate cancer: Cleveland Clinic experience. Int J Radiat Oncol Biol Phys 68(5):1424–1430
15. Bentzen SM, Dör R, Gabbaher R, Howell RW, Joiner MC, Jones B, Jones DT, van der Kogel AJ, Wammersie A, Whitmore G (2012) Bioeffect modeling and qequtive dose concepts in radiation oncology — terminology, quantities and units. Radiat Oncol 105(2):266–268
16. Michalski JM, Gay H, Jackson A, Tucker SL, Deasy JO (2010) Radiation dose-volume effects in radiation-induced rectal injury. Int J Radiat Oncol Biol Phys 76(3):S123–S129
17. Withers HR, Thames HD, Peters LJ (1983) A new iso-effect curve for change in dose per fraction. Radiother Oncol 1:187–191
18. Valsagri R, Kattan MW, Rancati T et al (2012) Is it time to tailor the prediction of radio-induced toxicity in prostate cancer patients? Building the first set of nomograms for late rectal syndrome. Int J Radiat Oncol Biol Phys 82(5):1957–1966
19. National Cancer Institute (2017) Common Terminology Criteria for Adverse Events 4.03 (CTCAE). http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm. Accessed May 2017
20. Al-Mamgani A, van Putten WL, Heemsbergen WD et al (2008) Update of Dutch multicenter dose escalation trial of radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 72(4):980–988
21. Zelefsky MJ, Levin DJ, Hunt M et al (2008) Incidence of late rectal and urinary toxicities after three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 70(4):1124–1129
22. Kuban DA, Tucker SL, Dong L et al (2008) Long-term results of the M.D. Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys 70(1):67–74
23. Ghadjar P, Jackson A, Spratt DE et al (2013) Patterns and predictors of amelioration of genitourinary toxicity after high-dose intensity-modulated radiation therapy for localized prostate cancer: implications for defining postradiotherapy urinary toxicity. Eur Urol 64(6):931–938
24. Aluwini S, Pos F, Schimmel E et al (2015) Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): acute toxicity results from a randomised non-inferiority phase 3 trial. Lancet Oncol 16(3):274–283
25. Mok G, Renz E, Vallee JP, Mirallbell R, Zilli T (2014) Optimization of radiation therapy techniques for prostate cancer with prostate-rectum spacers: a systematic review. Int J Radiat Oncol Biol Phys 90(2):278–288
26. Pinkawa M (2014) Spacer application for prostate cancer radiation therapy. Future Oncol 10(5):851–864
27. Uhl M, Van Triest B, Eble MJ, Weber DC, Herfarth K, De Weese TL (2013) Low rectal toxicity after dose escalated IMRT treatment of prostate cancer using an absorbable hydrogel for increasing and maintaining space between the rectum and prostate: results of a multi-institutional phase II trial. Radiother Oncol 106(2):215–219
28. Song DY, Herfarth KK, Uhl M et al (2013) A multi-institutional clinical trial of rectal dose reduction via injected polyethylene-glycol hydrogel during intensity modulated radiation therapy for prostate cancer: analysis of dosimetric outcomes. Int J Radiat Oncol Biol Phys 87(1):81–87
29. Strom TJ, Wilder RB, Fernandez DC et al (2014) A dosimetric study of polyethylene glycol hydrogel in 200 prostate cancer patients treated with high-dose rate brachytherapy ± intensity modulated radiation therapy. Radiother Oncol 111(1):126–131
30. Mariados N, Sylvester J, Shah D et al (2015) Hydrogel spacer prospective multicenter randomized controlled pivotal trial: dosimetric and clinical effects of perirectal spacer application in men undergoing prostate image guided intensity modulated radiation therapy. Int J Radiat Oncol Biol Phys 92(5):971–977
31. Pinkawa M, Berneking V, König L, Frank D, Bretgeld M, Eble MJ (2017) Hydrogel injection reduces rectal toxicity after radiotherapy for localized prostate cancer. Strahlenther Onkol 193(1):22–28
32. Hoogeman MS, van Herk M, de Bois J, Lebesque JV (2005) Strategies to reduce the systematic error due to tumor and rectum motion in radiotherapy of prostate cancer. Radiother Oncol 74(2):177–185
33. Huang TC, Chou KT, Yang SN, Chang CK, Liang JA, Zhang G (2015) Fractionated changes in prostate cancer radiotherapy using cone-beam computed tomography. Med Dosim 40(3):222–225
34. Chen Z, Yang Z, Wang J, Hu W (2016) Dosimetric impact of different bladder and rectum filling during prostate cancer radiotherapy. Radiat Oncol 2(11):103

35. Hedrick SG, Fagundes M, Case S, Renegar J, Blakey M, Artz M, Chen H, Robison B, Schreuder N (2017) Validation of rectal sparing throughout the course of proton therapy treatment in prostate cancer patients treated with SpaceOAR. J Appl Clin Med Phys 18:82–89